Related Experiment Video
Updated: Jul 16, 2025
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Single-cell transcriptomics identify TNFRSF1B as a novel T-cell exhaustion marker for ovarian cancer
Yan Gao1, Hui Shi2,3, Hongyu Zhao1
1Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, China.
Background:
Ovarian cancer (OC) patients routinely show poor immunotherapeutic response due to the complex tumour microenvironment (TME). It is urgent to explore new immunotherapeutic markers.
Methods:
Through the single-cell RNA sequencing (scRNA-seq) analyses on high-grade serous OC (HGSOC), moderate severity borderline tumour and matched normal ovary, we identified a novel exhausted T cells subpopulation that related to poor prognosis in OC. Histological staining, multiple immunofluorescences, and flow cytometry were applied to validate some results from scRNA-seq. Furthermore, a tumour-bearing mice model was constructed to investigate the effects of TNFRSF1B treatment on tumour growth in vivo.
Results:
Highly immunosuppressive TME in HGSOC is displayed compared to moderate severity borderline tumour and matched normal ovary. Subsequently, a novel exhausted subpopulation of CD8+ TNFRSF1B+ T cells is identified, which is associated with poor survival. In vitro experiments demonstrate that TNFRSF1B is specifically upregulated on activated CD8+ T cells and suppressed interferon-γ secretion. The expression of TNFRSF1B on CD8+ T cells is closely related to OC clinical malignancy and is a marker of poor prognosis through 140 OC patients' verification. In addition, the blockade of TNFRSF1B inhibits tumour growth via profoundly remodeling the immune microenvironment in the OC mouse model.
Conclusions:
Our transcriptomic results analyzed by scRNA-seq delineate a high-resolution snapshot of the entire tumour ecosystem of OC TME. The major applications of our findings were an exhausted subpopulation of CD8+ TNFRSF1B+ T cells for predicting OC patient prognosis and the potential therapeutic value of TNFRSF1B. These findings demonstrated the clinical value of TNFRSF1B as a potential immunotherapy target and extended our understanding of factors contributing to immunotherapy failure in OC.
Insights
Researchers identified a novel exhausted T cell subpopulation, CD8+ TNFRSF1B+ T cells, linked to poor ovarian cancer prognosis. Blocking TNFRSF1B shows therapeutic potential by remodeling the tumor microenvironment.
Area of Science:
- Immunology
- Oncology
- Genomics
Background:
- Ovarian cancer (OC) patients often exhibit poor responses to immunotherapy due to a complex tumor microenvironment (TME).
- Identifying novel immunotherapeutic markers is crucial for improving treatment outcomes in OC.
Purpose of the Study:
- To identify novel biomarkers and therapeutic targets within the OC tumor microenvironment.
- To investigate the role of a specific T cell subpopulation and TNFRSF1B in OC prognosis and treatment.
Main Methods:
- Single-cell RNA sequencing (scRNA-seq) was performed on high-grade serous OC, borderline tumors, and normal ovarian tissue.
- Histological staining, immunofluorescence, and flow cytometry were used for validation.
- A mouse model was employed to assess the therapeutic effect of TNFRSF1B blockade.
Main Results:
- A novel exhausted CD8+ TNFRSF1B+ T cell subpopulation associated with poor prognosis was identified in OC.
- TNFRSF1B was found to be upregulated on activated CD8+ T cells, suppressing interferon-γ secretion.
- TNFRSF1B expression correlated with OC clinical malignancy, and its blockade inhibited tumor growth in a mouse model.
Conclusions:
- The study identified CD8+ TNFRSF1B+ T cells as a prognostic marker for OC patients.
- TNFRSF1B represents a potential immunotherapy target for ovarian cancer, offering insights into immunotherapy resistance mechanisms.
